## South East London Area Prescribing Committee
### Formulary recommendation

<table>
<thead>
<tr>
<th>Reference</th>
<th>014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intervention:</strong></td>
<td>Levonorgestrel (Jaydess®) Intrauterine device for use in contraception. Jaydess® is a levonorgestrel intrauterine system (LNG-IUS) for use in contraception. It is smaller, lower dose and shorter duration of use version of Mirena® LNG-IUS. It contains 13.5mg of levonorgestrel for contraceptive cover lasting 3 years.</td>
</tr>
<tr>
<td><strong>Date of Decision</strong></td>
<td>August 2014</td>
</tr>
<tr>
<td><strong>Date of Issue:</strong></td>
<td>September 2014</td>
</tr>
<tr>
<td><strong>Recommendation:</strong></td>
<td>Green – can be prescribed within agreed criteria for use in primary care within its licensed indication (see below).</td>
</tr>
</tbody>
</table>

### Further Information
- The license for Jaydess® covers use in contraception only and as licensed alternatives are available the requested use in potential gynaecological intervention e.g. in dysmenorrhea is not recommended.
- It is recommended that Jaydess® should only be inserted by physicians/healthcare providers who are experienced in IUS insertions and/or have undergone training on the Jaydess insertion procedure.
- This recommendation should be brought to the attention of local authorities who are commissioning sexual health services.
- The small size of the device would imply that women may prefer this over other long acting intrauterine devices due to supposed less painful insertion, particularly in young nulliparous women.

### Shared Care/Transfer of care document required:
- No

### Cost Impact for agreed patient group
- Likely to be cost neutral.

### Usage Monitoring & Impact Assessment
- Jaydess is subject to additional monitoring (black triangle drug); therefore reporting suspected adverse reactions after authorisation of the medicinal product is important via the Yellow Card Scheme.
- CCGs to liaise with Local Authorities regarding this recommendation where relevant for local contraceptive services.

### Evidence reviewed
#### References

NOTES:
   a) Area Prescribing Committee recommendations and minutes are available publicly on member CCG websites.
   b) This Area Prescribing Committee recommendation has been made on the cost effectiveness, patient outcome and safety data available at the time. The recommendation will be subject to review if new data becomes available, costs are higher than expected or new NICE guidelines or technology appraisals are issued.
   c) Not to be used for commercial or marketing purposes. Strictly for use within the NHS